Academic and Industry Leaders Pursue Industrial Applications of Synthetic Biology

Pre-Clinical Study Aims to Predict Human Toxicity  

Companies To Leverage Adnexus' Proprietary Adnectin-PROfusion Product Engine For Advanced Biologics

Princeton, NJ and Waltham, MA, February 26, 2007 -- Bristol-Myers Squibb Company (NYSE:BMY) and Adnexus Therapeutics today announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for important oncology-related targets.

CAMBRIDGE, MASS., February 28 /CNW/ - Helicos BioSciences Corporation today announced it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be offered will be sold by the company. The number of shares to be sold in the proposed offering and the offering price have not yet been determined.

American – Dutch Technology Partnership to Explore Collaborative Research to Accelerate Commercialization of Lignocellulosic Ethanol

Woburn, MA -- March 6, 2007 –VisEn Medical today announced the launch of a multi-year joint research and development program with Merck & Co., Inc. to develop and apply a range of fluorescence imaging agents for real-time imaging of key disease biomarkers in vivo.

Company Positioned for Biofuel Breakthroughs and Commercialization

Pioneer in regenerative cell-based therapies and devices kicks off patient recruitment for Phase II clinical safety trials of first biologically-active treatment to ameliorate acute vascular injury in multiple disease states

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced that it has begun enrolling patients in two Phase II clinical trials of the company’s first product, Vascugel™.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in cellulosic biomass-to-biofuels development and production, today announced the appointment of Bruce A. Jamerson as its Chief Executive Officer and member of the Board of Directors. He was previously President of VeraSun Energy Corporation, a leading ethanol producer based in Brookings, South Dakota. Mr. Jamerson will apply his experience in ethanol, energy and finance to the company’s strategic initiatives and operations.

Eisai’s Dramatic Leap towards Biologic Therapeutics Evidenced by the Acquisition